THE PHARMACOKINETIC EFFECTS OF SEPRANOLONE

THE PHARMACOKINETIC EFFECTS OF SEPRANOLONE

The physiological and neurological effects of ALLO are clear and well-known, with its potential as a pharmaceutical treatment long discussed. In a 2006 study – Pharmacokinetic and behavioral effects of Allopregnanolone in healthy women – ALLO-induced physical signals were demonstrated in women given three different doses of ALLO. ALLO-induced sedation and reduced Saccadic Eye Velocity (SEV), a recognized marker on the activation of the GABA-A system, were observed (1).

In vivo studies also show the effect of Sepranolone in reducing the physical and behavioral effects of ALLO. In preclinical rat models Sepranolone significantly ameliorated ALLO-induced anaesthesia (2) and ALLO-induced anxiety and oestrus-cycle dependent aggressivity (3). University of Utah research showed Sepranolone reduced tics in a D1CT-7 mouse model of Tourette’s syndrome without inducing any motor side effects (4).

(1) GABAA receptor modulating steroids in acute and chronic stress; relevance for cognition and dementia? (2020, Bengtsson et al.) (2) Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats (April 2005 Bäckström et al) (3) Internal Asarina Pharma research reports 2008, 2009, 2013 11. (4) Allopregnanolone mediates the exacerbation of Tourette-like responses by acute stress in mouse models (June 2017, Bortolato et al.)